Clinical Trials Sponsored by Ontario Clinical Oncology Group (OCOG)

Total 356 results

Ontario Clinical Oncology Group (OCOG)

Recruiting

Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy (ROSALIE)

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)

Recruiting

A Randomized Trial of Five Fraction Partial Breast Irradiation

Breast Neoplasm Female | Radiotherapy | Cosmetic Outcome

Canada
Ontario Clinical Oncology Group (OCOG)

Recruiting

Hypofractionated LocoRegional Radiotherapy in Breast Cancer (RHEAL)

Breast Neoplasms | Lymphedema | Radiotherapy

Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Assessment of New Molecular Imaging Strategies for Prostate Cancer (MISTER)

Prostate Cancer

Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Evaluation of the DCIS Score for Decisions on Radiotherapy in Patients With Low/Intermediate Risk DCIS (DUCHESS)

DCIS

Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Study To Investigate the Feasibility and Safety of A Dedicated High Resolution Nuclear Breast Imaging Camera (THORN)

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)

Recruiting

Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS) (ELISA)

DCIS

Canada
Ontario Clinical Oncology Group (OCOG)

Terminated

Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (PETRA)

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy (IMPACT)

Locally Advanced Breast Cancer (LABC)

Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy With Temporary Iridium Implant Plus External Beam Radiation in Carcinoma of the Prostate

Prostate Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Pfizer

Completed

Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)

Ovarian Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
AstraZeneca

Completed

Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy (ELAAT)

Prostate Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
AstraZeneca

Completed

Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer (ZAMBONEY)

Metastatic Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Pfizer

Completed

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

Venous Thromboembolism | Brain Tumors

United States, Canada, Australia, Italy
Ontario Clinical Oncology Group (OCOG)
Cancer Care Ontario

Active, not recruiting

Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging (PET MUSE)

Muscle-invasive Bladder Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Cancer Care Ontario

Completed

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer (PET ABC)

Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4) | Stage IIb Breast Cancer (T3N0)

Canada
Ontario Clinical Oncology Group (OCOG)
NCIC Clinical Trials Group

Completed

Shorter Radiation Schedule for the Treatment of Prostate Cancer

Prostate Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals

Terminated

A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy (DOVE-M)

Advanced Malignant Pleural Mesothelioma | MPM

Canada
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals

Completed

Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA)

Breast Cancer

United States, Canada
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals

Completed

A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)

Recurrent Adenoid Cystic Carcinoma of the Salivary Glands | Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | Salivary Gland Cancers | ACC

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Cancer Research Network

Completed

The Roles of Tissue Factor in Malignant Gliomas

Venous Thromboembolism | Brain Tumors

United States, Canada
Ontario Clinical Oncology Group (OCOG)
Ortho Biotech, Inc.

Terminated

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

Anemia | Lung Cancer | Non-Small-Cell Lung Carcinoma

Canada
Ontario Clinical Oncology Group (OCOG)
Bristol-Myers Squibb

Active, not recruiting

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)

Metastatic Renal Cell Carcinoma

Canada, Australia
Ontario Clinical Oncology Group (OCOG)
Hoffmann-La Roche

Recruiting

Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy (ADVANCE HCC)

Hepatocellular Carcinoma | Portal Vein Tumour Thrombosis

Canada
Bristol-Myers Squibb
Ontario Clinical Oncology Group (OCOG)

Completed

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Cancer | Thrombosis | Pulmonary Embolism

United States, Canada
Ontario Clinical Oncology Group (OCOG)
Hoffmann-La Roche

Completed

A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL (CATCH)

HIV Infections | Lymphoma, AIDS Related

Canada
Ontario Clinical Oncology Group (OCOG)
Roche Pharma AG

Completed

Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

Non-small Cell Lung Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Canadian Cancer Society (CCS)

Completed

A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy (BRACHY)

Non-small Cell Lung Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Juravinski Cancer Centre Foundation

Completed

A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant Chemotherapy (PETLAB)

Locally Advanced Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
British Columbia Cancer Agency

Active, not recruiting

A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer (LUMINA)

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Canadian Cancer Society (CCS)

Completed

Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients (LUSTRE)

Non-small Cell Lung Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Canadian Breast Cancer Initiative

Completed

Randomized Trial of Follow-up Strategies in Breast Cancer

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Canadian Breast Cancer Foundation

Completed

Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation (OPAR)

Breast Cancer | DCIS

Canada
Ontario Clinical Oncology Group (OCOG)
Aboca Spa Societa' Agricola

Completed

Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population (ABOCA1)

Asbestos Exposure

Canada
Janssen-Ortho Inc., Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Carcinoma | Prostate
Ontario Clinical Oncology Group (OCOG)
Canadian Breast Cancer Research Alliance

Completed

Accelerated Radiotherapy Outcomes in Women

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Canadian Breast Cancer Research Alliance

Completed

Trial of Decongestive Lymphatic Therapy for Lymphedema in Women With Breast Cancer "DELTA STUDY"

Breast Cancer | Lymphedema

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

A Prospective Cohort Study to Evaluate the Oncotype DX® Test in Early Stage Breast Cancer (ONCOTYPEDX)

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study (PETREC)

Lymphoma | Breast Cancer | Head and Neck Cancer | Esophageal Cancer | Ovarian Cancer | Non-small Cell Lung Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial) (PET LACE)

Adenocarcinoma | Cervical Cancer | Squamous Cell Carcinoma | Adenosquamous Carcinoma

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases (PETCAM)

Colorectal Cancer | Liver Metastases

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers (ELPET)

Non-small-cell Lung Carcinoma

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial)

Cancer of the Head and Neck

Canada
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)

Non-Small-Cell Lung Carcinoma

Canada
Hamilton Health Sciences Corporation
McMaster University; Ontario Clinical Oncology Group (OCOG)

Not yet recruiting

Infection Prophylaxis in Total Joint Replacement (PREVENT-iT)

Periprosthetic Joint Infection
Ontario Clinical Oncology Group (OCOG)
Canadian Institutes of Health Research (CIHR)

Terminated

Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy (ALMERA)

Lung Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Canadian Institutes of Health Research (CIHR)

Completed

Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1

Cervical Intraepithelial Neoplasia

Canada, Brazil
Toronto Sunnybrook Regional Cancer Centre
Ontario Clinical Oncology Group (OCOG); Ontario Cancer Research Network

Completed

Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer

Non-Small Cell Lung Cancer

Canada

Clinical Trials Sponsored by Ontario Clinical Oncology Group (OCOG)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations